Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | CTSA | P10619 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5720924 | 1.00 | KMT2A (0.66) | KMT2ASMN1; SMN2L3MBTL1LMNAMTNR1A | |
| SCHEMBL29592469 | 1.00 | KMT2A (0.66) | KMT2ASMN1; SMN2L3MBTL1LMNAMTNR1A | |
| SCHEMBL1686398 | 1.00 | KMT2A (0.66) | KMT2ASMN1; SMN2L3MBTL1LMNAMTNR1A | |
| Hydrochloric Acid SCHEMBL28810293 | 0.98 | KMT2A (0.64) | KMT2ASMN1; SMN2L3MBTL1LMNAMTNR1A | |
| SCHEMBL20546225 | 0.91 | CTSA (0.59) | KMT2ASMN1; SMN2L3MBTL1LMNAFFAR1 | |
| SCHEMBL20546229 | 0.91 | CTSA (0.59) | KMT2ASMN1; SMN2L3MBTL1LMNAFFAR1 | |
| SCHEMBL6185468 | 0.86 | L3MBTL1 (0.58) | KMT2ASMN1; SMN2L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2969889 | 0.86 | KMT2A (0.64) | KMT2ASMN1; SMN2L3MBTL1FFAR1 | |
| SCHEMBL20545760 | 0.86 | FFAR1 (0.56) | KMT2ASMN1; SMN2L3MBTL1LMNAFFAR1 | |
| SCHEMBL20545762 | 0.86 | FFAR1 (0.56) | KMT2ASMN1; SMN2L3MBTL1LMNAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| EP-3305900-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2021-07-21 | — | — | EP | disclosed |
| US-20200216836-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2020-07-09 | — | — | US | disclosed |
| US-20190330618-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2019-10-31 | — | — | US | disclosed |
| US-10287576-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2019-05-14 | — | — | US | disclosed |
| US-20170247688-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2017-08-31 | — | — | US | disclosed |
| US-20170247688-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2017-08-31 | — | — | US | disclosed |
| EP-2336315-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | disclosed |
| US-9574189-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2017-02-21 | — | — | US | disclosed |
| EP-2341140-A1 | Enzymatic encoding methods for efficient synthesis of large libraries | Nuevolution A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| EP-2336315-A2 | Enzymatic encoding methods for efficient synthesis of large libraries | Nuevolution A/S (DK) | 2011-06-22 | — | — | EP | disclosed |
| EP-1957644-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2009-10-22 | — | — | US | disclosed |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2009-10-22 | — | — | US | disclosed |
| WO-2007062664-A2 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2007-06-07 | — | — | WO | disclosed |
| EP-1183241-B1 | SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2003-09-17 | — | — | EP | disclosed |
| US-6399643-B1 | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-04 | — | — | US | disclosed |
| EP-1183241-A1 | SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069831-A1 | SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | RNGTT, DUT, EMG1 | KMT2A 1082/4885SMN1; SMN2 3626/4885L3MBTL1 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.